Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders (the "Annual Meeting") of Protara Therapeutics, Inc. (the "Company") was held on June 12, 2026. As of April 15, 2026, the record date for the Annual Meeting, there were 55,060,500 shares of the Company's common stock outstanding and entitled to vote. A summary of the matters voted upon at the Annual Meeting and the final voting results are set forth below.

Proposal 1. Election of Directors.

The Company's stockholders elected the three persons listed below as Class III directors, each to serve on the Company's Board of Directors until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm.

The Company's stockholders ratified the selection by the Company's Audit Committee of the Board of Ernst and Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

Proposal 3. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers.

The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's definitive proxy statement for the Annual Meeting. The final voting results are as follows:

Proposal 4. Vote, on an Advisory Basis, on the Frequency of the Say-On-Pay vote.

The Company's stockholders voted, on an advisory basis, that the stockholder advisory vote to approve the compensation of the Company's named executive officers should occur every one year. The final voting results are as follows: